Potential efficacy of vosoritide for foramen magnum stenosis in a patient with achondroplasia.
Published In: Pediatrics International, 2025, v. 67, n. 1. P. 1 1 of 3
Database: Academic Search Ultimate 2 of 3
Authored By: Suzuki, Mitsuyoshi; Sakamoto, Koichiro; Sakurai, Yumiko; Saito, Hiroki; Nakano, Satoshi; Nishizaki, Naoto 3 of 3
Abstract
The article focuses on the therapeutic effects of vosoritide, a C-type natriuretic peptide analog, in treating achondroplasia and its associated complications, particularly foramen magnum stenosis (FMS). Vosoritide targets the overactive fibroblast growth factor receptor 3 (FGFR3) pathway, promoting bone growth and improving skeletal development in children. A case report details the treatment of a 26-month-old boy with FMS, highlighting significant improvements in his condition after starting vosoritide at 6 months old, including a reduction in FMS severity and normal developmental milestones. The article also notes ongoing studies to further evaluate the efficacy of vosoritide in younger patients with achondroplasia. [Extracted from the article]
Additional Information
- Source:Pediatrics International. 2025/01, Vol. 67, Issue 1, p1
- Document Type:Article
- Subject Area:Health and Medicine
- Publication Date:2025
- ISSN:1328-8067
- DOI:10.1111/ped.70106
- Accession Number:190445156
- Copyright Statement:Copyright of Pediatrics International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Looking to go deeper into this topic? Look for more articles on EBSCOhost.